Acute Myocardial Injury Following **COVID-19 Vaccination**

Pathum sookaromdee¹ and Viroj Wiwanitkit²

Dates received: 29 July 2021; accepted: 29 July 2021.

Dear Editor,

We would like to share ideas on "Acute Myocardial Injury Following COVID-19 Vaccination: A Case Report and Review of Current Evidence from Vaccine Adverse Events Reporting System Database.¹" Deb et al mentioned that "Review of the Vaccine Adverse Events Reporting System (VAERS) in the Centers for Disease Control and Prevention be vigilant about the possibility of new adverse events.¹" The myocardial injury following vaccination is sporadically reported and it might be underreported since self-limitation is possible.² Regarding the reported elderly case,¹ there are many possible underlying pathomechanism. Deb et al noted that it was a result of an acute immune response but there is no data on immune change or pathological autoimmunity. In this case, there might be an underlying cardiovascular condition and the given vaccine might induce thrombohemostasis alteration. In a previous report, the COVID-19 vaccination can result in increased blood viscosity which might be an important leading cause of myocardial disease.3

Declaration of Conflicting Interests

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding

The author(s) received no financial support for the research, authorship, and/or publication of this article.

ORCID iD

Pathum sookaromdee (D) https://orcid.org/0000-0002-8859-5322

References

- 1. Deb A, Abdelmalek J, Iwuji K, Nugent K. Acute myocardial injury following COVID-19 vaccination: a case report and review of current evidence from vaccine adverse events reporting system database. J Prim Care Community Health. 2021;12:21501327211029230.
- 2. Park J. Brekke DR. Bratincsak A. Self-limited myocarditis presenting with chest pain and ST segment elevation in adolescents after vaccination with the BNT162b2 mRNA vaccine. Cardiol Young. Published online June 28, 2021. doi:10.1017/S1047951121002547
- 3. Joob B, Wiwanitkit V. Expected viscosity after COVID-19 vaccination, hyperviscosity and previous COVID-19. Clin Appl Thromb Hemost. 2021;27:10760296211020833.

¹Private Academic Consultant, Bangkok, Thailand ²Dr DY Patil University, Pune, India

Corresponding Author:

Pathum Sookaromdee, Private Academic Consultant, Bangkok 104004, Thailand

Email: pathumsook@gmail.com

 (\mathbf{i})

Creative Commons Non Commercial CC BY-NC: This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).

Journal of Primary Care & Community Health Volume 12: I © The Author(s) 2021 Article reuse guidelines: sagepub.com/iournals-permissions DOI: 10.1177/21501327211039986 journals.sagepub.com/home/jpc (\$)SAGE